| Date | Title | Description |
| 16.06.2026 | SonoThera Secures $125M: Ultrasound Reshapes Genetic Medicine | SonoThera, a biotechnology pioneer, just closed a significant Series B funding round. The South San Francisco-based firm secured $125 million. This oversubscribed financing fuels its revolutionary nonviral genetic medicine platform. The inv... |
| 10.06.2026 | SonoThera Raises $125 Million Series B To Advance Ultrasound-Mediated Genetic Medicines | SonoThera, a biotechnology company developing ultrasound-mediated nonviral genetic medicines, announced the closing of an oversubscribed $125 million Series B financing round to support the clinical advancement of its lead programs for Duch... |
| 10.06.2026 | SonoThera Raises $125M in Series B Funding | SonoThera, a South San Francisco, CA-based biotechnology company developing new genetic medicines, raised $125M in Series B funding.
The round was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bay... |
| 04.03.2026 | Poplar Therapeutics Raises $45M in Series A Extension Funding | Poplar Therapeutics, a Cambridge, MA-based clinical-stage immunology company, raised $45M in Series A extension funding.
The round was led by Janus Henderson Investors, with participation from RA Capital, SR One, Vida Ventures and affiliate... |
| 03.03.2026 | Poplar Therapeutics: $45 Million Series A Extension Raised By Immunology Company To Advance Anti-IgE Therapy PHB-050 | Poplar Therapeutics, a clinical-stage immunology company developing a new class of anti-IgE therapy for food allergy and other atopic conditions, has closed a $45 million Series A extension, bringing its total Series A financing to $95 mill... |
| 08.01.2026 | Poplar Therapeutics Raises $50M in Series A Funding | Poplar Therapeutics, Inc. (previously known as Phylaxis Bioscience), a Boston, MA-based clinical-stage immunology company, raised $50m in Series A financing.
The round was led by SR One, Vida Ventures and Platanus.
The company intends to us... |
| 08.01.2026 | Poplar Therapeutics Launched With $50 Million Series A To Advance Anti-IgE Therapy for Multiple Atopic Conditions | Poplar Therapeutics has launched as a clinical-stage immunology company with a $50 million Series A financing to advance PHB-050, a next-generation anti-IgE antibody being developed for food allergy and other atopic conditions such as asthm... |
| 01.12.2025 | Protego Biopharma: $130 Million Series B Funding Closed To Advance Pivotal AL Amyloidosis Program | Protego Biopharma has closed an oversubscribed $130 million Series B financing round that will accelerate its first-in-class AL amyloidosis therapeutic program into a pivotal clinical study. The round was led by Novartis Venture Fund and Fo... |
| 07.10.2025 | Langer family RNA biotech Soufflé rises with $200M and Big Pharma partners | A new RNA biotech has risen with a $200 million series A in the tank and a team of seasoned biotech chefs ready to light the burners. Soufflé Therapeutics will cook up siRNA medicines that are targeted and cell-specific, the newly hatched c... |
| 29.07.2024 | Scorpion Therapeutics: A Bold Leap in Precision Oncology | Scorpion Therapeutics is making waves in the world of cancer treatment. With a recent $150 million Series C funding round, the Boston-based biotech is poised to redefine the landscape of precision oncology. This funding is not just a financ... |
| 27.07.2024 | Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline | Scorpion Therapeutics, a clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, announced the closing of a $150 million Series C financing. The funding was co... |
| 25.07.2024 | Canadian Startups Surge: Clio and Third Arc Bio Lead the Charge**
** | ** In the world of startups, the spotlight often shines brightest on Silicon Valley. Yet, this week, Canadian startups have taken center stage, proving that innovation knows no borders. Two companies, Clio and Third Arc Bio, have made headl... |
| 23.07.2024 | Third Arc Bio Launches with Oversubscribed $165 Million Series A Financing to Deliver Superior Biologics for Solid Tumors and Inflammatory & Immunology (I&I) Diseases | -- Company formed and originally seeded by Omega Funds, Series A financing with exceptional syndicate led by Vida Ventures
-- World-class leadership team led by Peter F. Lebowitz, MD, PhD, Sanjaya Singh, PhD, and Joe Erhardt, PhD, well-posi... |
| 23.07.2024 | Third Arc Bio launches with $165M to address unmet needs in oncology and autoimmunity | The company was founded by executives from Johnson & Johnson
Third Arc Bio is a company that says its on mission to deliver transformational therapies for solid tumors and inflammatory & immunology diseases through the use of multif... |
| 23.05.2024 | Venture Leaders Biotech 2024: Captains Blog by Maria Van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabs | Venture Leaders Biotech 2024: Captains Blog by Maria Van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabs 23.05.2024 12:30, Rita Longobardi linkedIn facebook twitter instagram youtube -->
In mid-May, the ten V... |
| 22.03.2022 | Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations | - |
| 04.07.2021 | Vida Ventures Closes Fund III, At $825M | Vida Ventures Leadership (from left to right): Rajul Jain, Stefan Vitorovic, Arjun Goyal, Arie Belldegrun, Jean-Philippe Kouakou-Zebouah, Helen S. Kim (Photo: Business Wire)
Vida Ventures, a Los Angeles, CA- and Boston, MA-based life scienc... |
| 24.06.2021 | Vida Ventures Closes $825 Million Vida III Fund to Advance Transformative Biomedical Innovations | - |
| 24.06.2021 | Andreessen Horowitz gears up for more mega crypto bets | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content Change your marketer experience and unleash growth for your business From Optimizely... |
| 24.06.2021 | Andreessen Horowitz gears up for more mega crypto bets | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content The gender pay gap and your investment strategies From Refinitiv
Venture capitalists... |
| 01.08.2019 | Vida Ventures Closes $600 Million Vida II Fund to Support Life Science Innovation | - |
| 01.08.2019 | Vida Ventures Closes Second Life Sciences Fund, at $600M | Vida Ventures, a Boston, MA-based next-generation life sciences venture capital firm, closed Vida Ventures II, LLC, at $600m.
Vida II investors include members of the Vida team, investors from the inaugural fund, top-tier endowments, founda... |
| 18.07.2019 | Vida Ventures Co-Leads $105 Million Series A Financing for Kronos Bio | BOSTON--(BUSINESS WIRE)--Vida Ventures, LLC (Vida), a next-generation life sciences venture firm, today announced that it co-led the $105 million Series A financing round for Kronos Bio (Kronos). Vida played a prominent role as a seed inves... |
| 18.07.2019 | Vida Ventures Co-Leads $105 Million Series A Financing for Kronos Bio | - |
| 15.04.2019 | Chapel Hill-Based AskBio Raises $225 Million From TPG Capital and Vida Ventures | - |
| 11.04.2019 | AskBio Lands $235M Financing From TPG And Vida Ventures | RESEARCH TRIANGLE PARK, N.C.& FORT WORTH, Texas & SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--Asklepios BioPharmaceutical, Inc (AskBio), a developer and manufacturer of Adeno-Associated Virus (AAV) gene therapy therapeutics for und... |
| 03.04.2018 | Vida Ventures Launches with Initial $295M in AUM; Invests in Allogene Therapeutics | Vida Ventures, a Boston, MA-based life sciences venture firm, was officially launched with an initial $295m in assets under management.
Founded in 2017 by Arie Belldegrun, Fred Cohen, Leonard Potter, Arjun Goyal, and Stefan Vitorovic, Vida ... |
| 03.04.2018 | Vida Ventures Unveils Next-Generation Life Sciences Venture Firm with $295 Million Under Management and an Investment in Allogene Therapeutics | - |
| 10.12.2017 | Vida Ventures Raises $254.8M Venture Capital Fund | Vida Ventures has raised a $254.8 million venture capital fund, according to a filing with the SEC.
The Boston-base firm is managed by Fred Cohen, Arie Belldegrun, Leonard Potter, Stefan Vitorovic and Arjun Goyal, according to the filing. F... |